VaxCorps, founded by Mark Lacy, CEO of VaxCorps and Benchmark Research, includes 130 highly experienced principal investigators and more than 850 additional staff who have completed over 2,000 trials. Over the past year, the VaxCorps network has conducted over 32 types of vaccine trials. Additionally, the VaxCorps global network was the first to have at least one company participate in over 97% of all vaccine trials over the last 12 months.
The VaxCorps network is committed to patient centricity and an openness to working with our industry partners to continue to advocate for diversity and equity in trials and decentralized methodologies to meet the demands both in timelines and accessibility.
Copyright © 2022 VaxCorps - All Rights Reserved.
VaxCorps - The Clinical Research Experts